These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 18544171)

  • 1. The SU.FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or Omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics.
    Galan P; Briancon S; Blacher J; Czernichow S; Hercberg S
    Trials; 2008 Jun; 9():35. PubMed ID: 18544171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Background and rationale of the SU.FOL.OM3 study: double-blind randomized placebo-controlled secondary prevention trial to test the impact of supplementation with folate, vitamin B6 and B12 and/or omega-3 fatty acids on the prevention of recurrent ischemic events in subjects with atherosclerosis in the coronary or cerebral arteries.
    Galan P; de Bree A; Mennen L; Potier de Courcy G; Preziozi P; Bertrais S; Castetbon K; Hercberg S
    J Nutr Health Aging; 2003; 7(6):428-35. PubMed ID: 14625623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B vitamin and/or ω-3 fatty acid supplementation and cancer: ancillary findings from the supplementation with folate, vitamins B6 and B12, and/or omega-3 fatty acids (SU.FOL.OM3) randomized trial.
    Andreeva VA; Touvier M; Kesse-Guyot E; Julia C; Galan P; Hercberg S
    Arch Intern Med; 2012 Apr; 172(7):540-7. PubMed ID: 22331983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supplementation with B vitamins or n-3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acids (SU.FOL.OM3) randomized trial.
    Andreeva VA; Galan P; Torrès M; Julia C; Hercberg S; Kesse-Guyot E
    Am J Clin Nutr; 2012 Jul; 96(1):208-14. PubMed ID: 22648722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial.
    Andreeva VA; Kesse-Guyot E; Barberger-Gateau P; Fezeu L; Hercberg S; Galan P
    Am J Clin Nutr; 2011 Jul; 94(1):278-86. PubMed ID: 21593490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B vitamin and/or n-3 fatty acid supplementation and health-related quality of life: ancillary findings from the SU.FOL.OM3 randomized trial.
    Andreeva VA; Latarche C; Hercberg S; Briançon S; Galan P; Kesse-Guyot E
    PLoS One; 2014; 9(1):e84844. PubMed ID: 24465438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.
    Galan P; Kesse-Guyot E; Czernichow S; Briancon S; Blacher J; Hercberg S;
    BMJ; 2010 Nov; 341():c6273. PubMed ID: 21115589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of B-vitamins and/or N-3 fatty acids: the SU.FOL.OM3 trial.
    Blacher J; Czernichow S; Paillard F; Ducimetiere P; Hercberg S; Galan P;
    Int J Cardiol; 2013 Jul; 167(2):508-13. PubMed ID: 22365647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MTHFR 677C → T genotype modulates the effect of a 5-year supplementation with B-vitamins on homocysteine concentration: The SU.FOL.OM3 randomized controlled trial.
    Fezeu LK; Ducros V; Guéant JL; Guilland JC; Andreeva VA; Hercberg S; Galan P
    PLoS One; 2018; 13(5):e0193352. PubMed ID: 29813097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.
    Albert CM; Cook NR; Gaziano JM; Zaharris E; MacFadyen J; Danielson E; Buring JE; Manson JE
    JAMA; 2008 May; 299(17):2027-36. PubMed ID: 18460663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of B-vitamins and n-3 PUFA supplementation for 5 years on blood pressure in patients with CVD.
    Szabo de Edelenyi F; Vergnaud AC; Ahluwalia N; Julia C; Hercberg S; Blacher J; Galan P
    Br J Nutr; 2012 Mar; 107(6):921-7. PubMed ID: 21801476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: the evidence revisited.
    Fezeu LK; Laporte F; Kesse-Guyot E; Andreeva VA; Blacher J; Hercberg S; Galan P
    PLoS One; 2014; 9(4):e92548. PubMed ID: 24710321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial.
    VITATOPS Trial Study Group
    Lancet Neurol; 2010 Sep; 9(9):855-65. PubMed ID: 20688574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease Current Evidence.
    Manson JE; Bassuk SS; Cook NR; Lee IM; Mora S; Albert CM; Buring JE;
    Circ Res; 2020 Jan; 126(1):112-128. PubMed ID: 31895658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
    ; Bonds DE; Harrington M; Worrall BB; Bertoni AG; Eaton CB; Hsia J; Robinson J; Clemons TE; Fine LJ; Chew EY
    JAMA Intern Med; 2014 May; 174(5):763-71. PubMed ID: 24638908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence.
    Bassuk SS; Manson JE;
    Cardiovasc Res; 2023 Jun; 119(6):1297-1309. PubMed ID: 36378553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL).
    Bassuk SS; Manson JE; Lee IM; Cook NR; Christen WG; Bubes VY; Gordon DS; Copeland T; Friedenberg G; D'Agostino DM; Ridge CY; MacFadyen JG; Kalan K; Buring JE
    Contemp Clin Trials; 2016 Mar; 47():235-43. PubMed ID: 26767629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin C supplementation for the primary prevention of cardiovascular disease.
    Al-Khudairy L; Flowers N; Wheelhouse R; Ghannam O; Hartley L; Stranges S; Rees K
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011114. PubMed ID: 28301692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omega-3 polyunsaturated fatty acids supplementation and cardiovascular outcomes: do formulation, dosage, and baseline cardiovascular risk matter? An updated meta-analysis of randomized controlled trials.
    Casula M; Olmastroni E; Gazzotti M; Galimberti F; Zambon A; Catapano AL
    Pharmacol Res; 2020 Oct; 160():105060. PubMed ID: 32634581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.